Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 11/20 | 0.69 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.69 |
| ▸ | DRD2 | P14416 | 2/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8347843 | 1.00 | ADRB2 (0.69) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL13197486 | 0.87 | ADRB2 (0.53) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL16716731 | 0.85 | ADRB2 (0.54) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL4458567 | 0.83 | ADRB2 (0.67) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL3628729 | 0.83 | ADRB2 (0.67) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL14118053 | 0.83 | ADRB2 (0.67) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL8347837 | 0.83 | ADRB2 (0.67) | ADRB2ADRB3ADRB1DRD2PGR | |
| Formoterol SCHEMBL15856256 | 0.82 | ADRB2 (1.00) | ADRB2ADRB3ADRB1DRD2PGR | |
| Arformoterol SCHEMBL6547706 | 0.82 | ADRB2 (1.00) | ADRB2ADRB3ADRB1DRD2PGR | |
| Arformoterol SCHEMBL458736 | 0.82 | ADRB2 (1.00) | ADRB2ADRB3ADRB1DRD2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305635-B1 | FORMOTEROL TARTRATE, PROCESS AND POLYMORPH | SUNOVION PHARMACEUTICALS INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9499475-B2 | Process for the preparation of arformoterol or salt thereof | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-9499475-B2 | Process for the preparation of arformoterol or salt thereof | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-20160083334-A1 | PROCESS FOR THE PREPARATION OF ARFORMOTEROL OR SALT THEREOF | GLENMARK LIFE SCIENCES LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
| US-20160083334-A1 | PROCESS FOR THE PREPARATION OF ARFORMOTEROL OR SALT THEREOF | GLENMARK LIFE SCIENCES LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
| WO-2014184756-A2 | PROCESS FOR THE PREPARATION OF ARFORMOTEROL OR SALT THEREOF | GLENMARK PHARMACEUTICALS LIMITED; GLENMARK GENERICS LIMITED (IN) | 2014-11-20 | — | — | WO | disclosed |
| US-20120108670-A1 | FORMOTEROL TARTRATE PROCESS AND POLYMORPH | SUNOVION PHARMACEUTICALS INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120053246-A1 | PURIFICATION PROCESS FOR PREPARING HIGHLY PURE ARFORMOTEROL TARTRATE SUBSTANTIALLY FREE OF DESFORMYL IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2012-03-01 | — | — | US | disclosed |
| US-8110706-B2 | Formoterol tartrate process and polymorph | SUNOVION PHARMACEUTICALS INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110706-B2 | Formoterol tartrate process and polymorph | SUNOVION PHARMACEUTICALS INC. (US) | 2012-02-07 | — | — | US | disclosed |
| EP-2165999-A1 | Formoterol tartrate process and polymorph | Sepracor Inc. (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-1446380-B1 | FORMOTEROL TARTRATE PROCESS AND POLYMORPH | SEPRACOR INC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090156862-A1 | Formoterol Tartrate Process and Polymorph | SEPRACOR INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156862-A1 | Formoterol Tartrate Process and Polymorph | SEPRACOR INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-7479572-B2 | Formoterol tartrate process and polymorph | SEPRACOR INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-7479572-B2 | Formoterol tartrate process and polymorph | SEPRACOR INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-20080114187-A1 | FORMOTEROL TARTRATE PROCESS AND POLYMORPH | SEPRACOR INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080114187-A1 | FORMOTEROL TARTRATE PROCESS AND POLYMORPH | SEPRACOR INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-7342132-B2 | Formoterol tartrate process and polymorph | SEPRACOR INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342132-B2 | Formoterol tartrate process and polymorph | SEPRACOR INC. (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156862-A1 | Formoterol Tartrate Process and Polymorph | ADRB1, ADRA1B, ADRA1A | ADRB2 5/4885ADRB3 7/4885ADRB1 1/4885 |
| US-20120108670-A1 | FORMOTEROL TARTRATE PROCESS AND POLYMORPH | ADRB1, ADRA1B, ADRA1A | ADRB2 5/4885ADRB3 7/4885ADRB1 1/4885 |
| US-20080114187-A1 | FORMOTEROL TARTRATE PROCESS AND POLYMORPH | ADRB1, ADRA1B, ADRA1A | ADRB2 5/4885ADRB3 7/4885ADRB1 1/4885 |
| US-20120053246-A1 | PURIFICATION PROCESS FOR PREPARING HIGHLY PURE ARFORMOTEROL TARTRATE SUBSTANTIALLY FREE OF DESFORMYL IMPURITY | ADRB1, ADRB2, ADRA1A | ADRB2 2/4885ADRB3 5/4885ADRB1 1/4885 |
| US-20160083334-A1 | PROCESS FOR THE PREPARATION OF ARFORMOTEROL OR SALT THEREOF | AGT, AGTR1, REN | ADRB2 8/4885ADRB3 14/4885ADRB1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.